Opinion|Videos|September 3, 2024
Optimizing BPH Management: Evaluating MIST Options and Key Treatment Considerations
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, compares minimally invasive surgical therapy (MIST) options for prostate treatment, discussing factors influencing choice, patient experience differences, and clinical and nonclinical factors such as prostate size, symptom severity, and patient preferences.
Advertisement
Video content above is prompted by the following:
- What are some of the key differences in the minimally invasive surgical therapy (MIST) options (prostatic urethral lift [PUL], water vapor thermal therapy, robotic waterjet treatment, photoselective vaporization of the prostate)?
- Please explain factors that may lead you to choose one MIST option over another.
- In terms of patient experience, what are some key differences in MIST options?
- Please speak of factors such as the need for local/general anesthesia, recovery time, time to symptom relief, preservation of sexual function, durability, etc.
- What clinical and nonclinical factors impact your treatment choice?
- Please speak to factors such as patient prostate size and symptom severity, common comorbidities, efficacy and durability, recovery time, and possible risks or adverse events.
- Does a PUL give you more confidence for treating a wide range of patients if the indication for prostate volume is larger (≤100 cc) compared with other options (30-80 cc)?
- What role does patient preference play in choosing the right treatment?
Advertisement
Related to this article
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Variation in PSMA PET Adoption for Prostate Cancer Care
3
Prostate Cancer Case Review: Biochemical Recurrence and a Rib Lesion
4
ENVISION data inform the use of chemoablation in recurrent LG-IR-NMIBC
5